ACADIA Pharmaceuticals Inc.
ACAD
Jodie situation report
ACADIA Pharmaceuticals Inc.'s current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- Revenue increased 16.4% versus the comparable filing period.
- ACAD's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if ACAD's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind ACAD
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
STOKStoke Therapeutics, Inc.partnerMay 7, 2026 ▾
“In January 2022, the Company entered into a license and collaboration agreement with Stoke Therapeutics, Inc.”
Depended on by
STOKStoke Therapeutics, Inc.partnerMar 16, 2026 ▾
“In addition, although we intend to establish a sales organization if we are able to obtain approval to market any product candidates, we have entered into a strategic alliance with Biogen to develop and commercialize zorevunersen outside of North America (the…”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ACAD is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.